SG Americas Securities LLC Decreases Position in Agios Pharmaceuticals, Inc. (AGIO)
SG Americas Securities LLC trimmed its position in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) by 2.9% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 8,190 shares of the biopharmaceutical company’s stock after selling 244 shares during the period. SG Americas Securities LLC’s holdings in Agios Pharmaceuticals were worth $421,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Bank of Montreal Can raised its holdings in shares of Agios Pharmaceuticals by 11.7% during the 1st quarter. Bank of Montreal Can now owns 2,068 shares of the biopharmaceutical company’s stock valued at $121,000 after buying an additional 216 shares in the last quarter. Blue Sky Asset Management LLC bought a new position in Agios Pharmaceuticals during the 1st quarter worth approximately $129,000. Russell Investments Group Ltd. grew its position in Agios Pharmaceuticals by 163.9% during the 1st quarter. Russell Investments Group Ltd. now owns 2,549 shares of the biopharmaceutical company’s stock worth $149,000 after acquiring an additional 1,583 shares during the last quarter. Soros Fund Management LLC bought a new position in Agios Pharmaceuticals during the 1st quarter worth approximately $228,000. Finally, Aperio Group LLC bought a new position in Agios Pharmaceuticals during the 2nd quarter worth approximately $206,000. 94.30% of the stock is currently owned by institutional investors.
AGIO has been the topic of several recent research reports. Canaccord Genuity set a $90.00 price target on Agios Pharmaceuticals and gave the stock a “buy” rating in a research report on Tuesday, August 8th. SunTrust Banks, Inc. restated a “buy” rating and set a $80.00 price target (up from $68.00) on shares of Agios Pharmaceuticals in a research report on Tuesday, August 8th. Oppenheimer Holdings, Inc. set a $75.00 price target on Agios Pharmaceuticals and gave the stock a “buy” rating in a research report on Thursday, June 1st. Cann restated a “buy” rating and set a $75.00 price target on shares of Agios Pharmaceuticals in a research report on Sunday, June 11th. Finally, BidaskClub upgraded Agios Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Thursday, July 13th. Four analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. The company currently has a consensus rating of “Buy” and an average target price of $74.75.
ILLEGAL ACTIVITY NOTICE: “SG Americas Securities LLC Decreases Position in Agios Pharmaceuticals, Inc. (AGIO)” was first posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this article on another publication, it was illegally copied and reposted in violation of US & international trademark and copyright legislation. The legal version of this article can be viewed at https://www.thecerbatgem.com/2017/09/13/sg-americas-securities-llc-decreases-position-in-agios-pharmaceuticals-inc-agio.html.
Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) opened at 66.11 on Wednesday. The stock has a 50 day moving average price of $59.33 and a 200-day moving average price of $54.04. Agios Pharmaceuticals, Inc. has a 12 month low of $39.24 and a 12 month high of $67.74. The company’s market capitalization is $3.20 billion.
Agios Pharmaceuticals (NASDAQ:AGIO) last issued its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($1.78) earnings per share for the quarter, missing the consensus estimate of ($1.57) by ($0.21). Agios Pharmaceuticals had a negative return on equity of 68.15% and a negative net margin of 502.12%. The business had revenue of $11.30 million during the quarter, compared to analysts’ expectations of $10.68 million. During the same quarter in the previous year, the company posted ($1.47) earnings per share. The company’s quarterly revenue was up 62.1% compared to the same quarter last year. Analysts expect that Agios Pharmaceuticals, Inc. will post ($7.07) earnings per share for the current fiscal year.
In related news, CEO David P. Schenkein sold 3,000 shares of the stock in a transaction that occurred on Monday, July 3rd. The stock was sold at an average price of $51.18, for a total value of $153,540.00. Following the transaction, the chief executive officer now owns 3,000 shares of the company’s stock, valued at $153,540. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, insider Scott Biller sold 2,146 shares of the stock in a transaction that occurred on Friday, July 7th. The stock was sold at an average price of $55.00, for a total value of $118,030.00. Following the completion of the transaction, the insider now directly owns 8,410 shares in the company, valued at approximately $462,550. The disclosure for this sale can be found here. Over the last quarter, insiders sold 84,230 shares of company stock worth $4,943,142. Company insiders own 10.55% of the company’s stock.
About Agios Pharmaceuticals
Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company’s cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.
Receive News & Stock Ratings for Agios Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.